Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
In the register
The register attaches this trial to EQ101 (BNZ-1) (Equillium), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Equillium
- Participants (registry)
- 36
- Start
- December 2022
- Primary completion
- March 2024
- Study completion
- April 2024
- Last registry update
- April 2025
- Countries
- Australia, New Zealand
Conditions studied: Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis
Interventions: EQ101
Other trials of EQ101 (BNZ-1)
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.